載入...
Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo
Combination treatment for non–small cell lung cancer (NSCLC) is becoming more popular due to the anticipation that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients for specific mutations in light of attempting to administer specific a...
Na minha lista:
| 發表在: | Neoplasia |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Neoplasia Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4351293/ https://ncbi.nlm.nih.gov/pubmed/25748238 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2014.12.008 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|